Dark Light

Advertisement


Recognition highlights IMC’s growing market momentum in Israel following the Company’s recent streamlining initiatives

IM Cannabis Corp. (“IMC” or the “Company”) (NASDAQ: IMCC) (CSE: IMCC), a leading medical and adult-use recreational cannabis company with operations in IsraelCanada and Germany, is pleased to announce that its legacy strain, Roma, has been voted as the Favourite Strain of the Month in August 2022 by ‘Cannabis’, one of Israel’s leading cannabis blogs for Israeli medical cannabis patients.[1] The Company believes its recent rebranding and restructuring initiatives have significantly contributed to the growing market momentum in Israel.

IM Cannabis Logo

IMC’s Roma strain is a high-THC medical cannabis flower that offers a therapeutic continuum and is known for its strength and longevity of effect. The Company’s Roma strain has been prescribed in Israel to help relieve chronic pain and migraines, and treat nausea, insomnia, eating disorders, and anxiety.

IMC unveiled a series of plans to strengthen its branding and operations in Israel, as stated in its press release dated April 6, 2022. As part of these efforts, Focus Medical Herbs Ltd., which has a commercial agreement with IM Cannabis to distribute its production under the IMC brand, expanded the Roma offering to include pre-rolls and an oils range. In addition, the Company streamlined its call centres for increased efficiency to offer its medical cannabis patients consistent, superior experience and information, in what is now the largest cannabis call centre in Israel.

In August 2022, 100 kilograms of Roma were sold in Israel. While the Company started with humble beginnings, today it is a leader of the premium and ultra-premium segments in the Israeli medical cannabis market. Over the past year, the Company has launched over 25 new SKUs, pioneering in craft flower, pre-rolls, full-spectrum oils and original Canadian brands and their original strains, such as WAGNERS, from its Canadian subsidiary Trichome Financial Corp. (“Trichome“) and others from its world-leading cannabis suppliers and partners.

Oren Shuster, IM Cannabis CEO commented: “I am pleased to see that our sharpened focus, new initiatives, and hard work are beginning to bear fruit. The fact that medical patients in Israel are voting for Roma, our legacy premium strain, is a testament to the realization of our mission. Over the years, we have embarked upon many journeys to improve the quality and composition of our products, and by selecting Roma as a favourite strain, Israeli medical cannabis patients have shown us that we are on the right track.”

TORONTO and GLIL YAM, IsraelOct. 26, 2022 /PRNewswire/

Source:IM Cannabis Corp

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts
Our site uses cookies. Learn more about our use of cookies: cookie policy

Sign Up for Our Newsletter